Correlation between stromal cell-derived factor 1 and the prognosis of transient ischemic attack

IRCMJ logo

Keywords

Cerebral infarction
Chemokine CXCL12
Transient ischemic attack

How to Cite

LiuM., XieJ., ZhengX., WangM., ChenG., WangT., & LuY. (2021). Correlation between stromal cell-derived factor 1 and the prognosis of transient ischemic attack. Iranian Red Crescent Medical Journal, 23(5). Retrieved from https://ircmj.com/index.php/IRCMJ/article/view/348

Abstract

Background: Transient Ischemic Attack (TIA) (1) is a neurological dysfunction of transient cerebrovascular ischemia, which is more common in clinical practice. The risk of further progression to ischemic stroke after a higher TIA can be used as a strong early warning signal of cerebral infarction.

Objectives: To explore the correlation between stromal cell-derived factor 1 (SDF-1) and the prognosis of TIA. 

Methods: A number of 65 patients with TIA were collected, the ABCD2 clinical risk prediction score was implemented, relevant tests and nuclear magnetic resonance imaging (MRI) were performed, and the SDF-1 was recorded in serum levels. End-point events were selected in patients after cerebral infarction in the short term. The statistical analysis method was used to evaluate TIA short-term development for the occurrence of cerebral infarction after risk, the severity of serum level of SDF-1, and infarction.

Results: Based on the results, the high-risk group, middle-risk group, and low-risk group had statistically significant differences in serum SDF-1 levels (F=3.820; P<0.05).  Correlation analysis demonstrated that ABCD2 score was positively correlated with serum SDF-1 (r=0.349; P<0.05).  End-point events were included in the occurrence group and not included in the non-occurrence group. The SDF-1 level of the occurrence group was significantly higher than that of the non-occurrence group.  Based on the cranial MRI results as the gold standard, the areas under the curve of the receiver operating characteristic curve (ROC) drawn based on the SDF-1, ABCD2 score, SDF-1 combined with the ABCD2 score, and the occurrence of end-point events were obtained at 0.717, 0.697, and 0.762, respectively.  The sensitivity and specificity of SDF-1 were reported as 77.8% and 68.1%, respectively. The sensitivity and specificity of the ABCD2 score were 83.3% and 48.9%, respectively. The sensitivity and specificity of SDF-1 combined with the ABCD2 score were 72.2% and 76.6%, respectively. 

 

Conclusion: As evidenced by the obtained results, SDF-1 is associated with ABCD2 score risk classification. Patients with high levels of SDF-1 combined with the ABCD2 score have a higher risk of cerebral infarction.  Elevated SDF-1 levels may indicate that TIA patients have a poor short-term prognosis and have a certain predictive value for the diagnosis of the risk of ischemic stroke in the short term.

References

  1. Simmatis LER, Scott SH, Jin AY. The impact of transient ischemic attack (TIA) on brain and behavior. Front Behav Neurosci. 2019;13:44. doi: 10.3389/fnbeh.2019.00044. [PubMed: 30914931].
  2. Amarenco P, Lavallée PC, Labreuche J, Albers GW, Bornstein NM, Canhão P, et al. One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med. 2016;374(16):1533-42. doi: 10.1056/NEJMoa1412981. [PubMed: 27096581].
  3. Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS, Bernstein AL, et al. Validation and refinement of scores to predict very early stroke risk after transient ischemic attack. Lancet. 2007;369(9558):283-92. doi: 10.1016/S0140-6736(07)60150-0. [PubMed: 17258668].
  4. Xi HY, Si ZH, Li JC, Zhu JG, Yan HY. Assessment of cerebral infarction after transient cerebral ischemic attack by ABCD2 score combined with the position of intracranial vascular stenosis. Medicine (Baltimore). 2019;98(15):e15081. doi: 10.1097/MD.0000000000015081. [PubMed: 30985660].
  5. Zhao W, Zhao L, Liao J, Luo Y, He L. Early risk assessment of circulating endothelial progenitor cells and plasma stromal cell-derived factor-1 for nondisabling ischemic cerebrovascular events. BMC Neurol. 2019;19(1):22. doi: 10.1186/s12883-019-1250-5. [PubMed: 30755169].
  6. The Chinese Society for Neurosurgery. Key points for diagnosis of various cerebrovascular diseases. Chin J Neurol. 1996;29(6):379-80.
  7. Kelly PJ, Albers GW, Chatzikonstantinou A, De Marchis GM, Ferrari J, George P, et al. Validation and comparison of imaging-based scores for prediction of early stroke risk after transient ischaemic attack: a pooled analysis of individual-patient data from cohort studies. Lancet Neurol. 2016;15(12):1238-47. doi: 10.1016/S1474-4422(16)30236-8. [PubMed: 27751555].
  8. Huan Y, Chaoyang Z, Kai D, Chunhua S, Xin Z, Yue Z. Predictive value of head-neck CTA combined with ABCD2 scale score for patients with cerebral infarction of vertebrobasilar transient ischemic attack (TIA). Med Sci Monit. 2018;24:9001-6. doi: 10.12659/MSM.909470. [PubMed: 30540723].
  9. Ingram N, Porter CD. Transcriptional targeting of acute hypoxia in the tumour stroma is a novel and viable strategy for cancer gene therapy. Gene Ther. 2005;12(13):1058-69. doi: 10.1038/sj.gt.3302504. [PubMed: 15800661].
  10. Zhou Z, Ren X, Zhou W, Zheng L. Willed‑movement training reduces middle cerebral artery occlusion‑induced motor deficits and improves angiogenesis and survival of cerebral endothelial cells via upregulating hypoxia‑inducible factor‑1α. Mol Med Rep. 2019;20(4):3910-6. doi: 10.3892/mmr.2019.10578. [PubMed: 31432135].
  11. Mollica Poeta V, Massara M, Capucetti A, Bonecchi R. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol. 2019;10:379. doi: 10.3389/fimmu.2019.00379. [PubMed: 30894861].
  12. Legler DF, Thelen M. Chemokines: chemistry, biochemistry and biological function. Chimia (Aarau). 2016;70(12):856-9. doi: 10.2533/chimia.2016.856. [PubMed: 28661356].
  13. Thored P, Arvidsson A, Cacci E, Ahlenius H, Kallur T, Darsalia V, et al. Persistent production of neurons from adult brain stem cells during recovery after stroke. Stem Cells. 2006;24(3):739-47. doi: 10.1634/stemcells.2005-0281. [PubMed: 16210404].
  14. Malone CD, Hasan SM, Roome RB, Xiong J, Furlong M, Opferman JT, et al. Mcl-1 regulates the survival of adult neural precursor cells. Mol Cell Neurosci. 2012;49(4):439-47. doi: 10.1016/j.mcn.2012.02.003. [PubMed: 22357134].
  15. Ardelt AA, Bhattacharyya BJ, Belmadani A, Ren D, Miller RJ. Stromal derived growth factor-1 (CXCL12) modulates synaptic transmission to immature neurons during post-ischemic cerebral repair. Exp Neurol. 2013;248:246-53. doi: 10.1016/j.expneurol.2013.06.017. [PubMed: 23811016].
  16. Li Y, Huang J, He X, Tang YH, Liu Y, Lin X, et al. Postacute stromal cell-derived factor-1α expression promotes neurovascular recovery in ischemic mice. Stroke. 2014;45(6):1822-9. doi: 10.1161/STROKEAHA.114.005078. [PubMed: 24876262].
  17. Lan TH, Xu DP, Huang MT, Song JX, Wu HL, Li M. Ginsenoside Rb1 prevents homocysteine-induced EPC dysfunction via VEGF/p38MAPK and SDF-1/CXCR4 activation. Sci Rep. 2017;7(1):13061. doi: 10.1038/s41598-017-13436-7. [PubMed: 29026158].
  18. Mao L, Huang M, Chen SC, Li YN, Xia YP, He QW, et al. Endogenous endothelial progenitor cells participate in neovascularization via CXCR4/SDF-1 axis and improve outcome after stroke. CNS Neurosci Ther. 2014;20(5):460-8. doi: 10.1111/cns.12238. [PubMed: 24581269].
  19. Huang X, Wan M, Yang Q, Ding X, Zhou Z. The stromal cell-derived factor-1 α (SDF-1α)/cysteine-X-cysteine chemokine receptor 4 (CXCR4) axis: a possible prognostic indicator of acute ischemic stroke. J Int Med Res. 2019;47(5):1897-907. doi: 10.1177/0300060519827173. [PubMed: 30760134].